Spectral Med Inc (EDT.TO) stock: key figures, P/E, revenue and dividend

Health Care · Biotechnology · Canada · ISIN CA8475771033

Price
0.93 CAD
Market cap
267.10 m CAD
P/E (2025)
–
P/S (2025)
109.38
Dividend yield
0.00 %
Net margin
-1,952.99 %
Return on equity (ROE)
68.40 %
Return on assets (ROA)
-781.84 %

Spectral Med Inc financials

Fiscal year20242025
Revenue2.29 m CAD2.44 m CAD
Gross profit1.02 m CAD-5.16 m CAD
Operating income-12.00 m CAD-11.69 m CAD
EBIT-12.22 m CAD-42.53 m CAD
Net income-15.40 m CAD-47.69 m CAD
Diluted EPS – continuing operations-0.05 CAD-0.17 CAD

Full history since 1992, charts and your own formulas

This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.

About Spectral Med Inc

Spectral Medical Inc. focuses on the development and commercialization of products for the treatment of septic shock in the United States, Italy, Ireland, Russia, and internationally. The company markets Endotoxin Activity Assay, a rapid in-vitro diagnostic test for the detection of components of gram negative; and Polymyxin B-Hemoperfusion, a therapeutic hemoperfusion device that removes endotoxin from the bloodstream. It also develops, manufactures, and markets monoclonal and polyclonal antibodies, recombinant cardiac proteins, antibodies, and calibrators for use in the research and development, as well as products that are manufactured by other diagnostic companies. The company was formerly known as Spectral Diagnostics Inc. and changed its name to Spectral Medical Inc. in December 2014. Spectral Medical Inc. was incorporated in 1991 and is headquartered in Toronto, Canada.

More stocks

All stocks →

Not investment advice. All data without warranty, price as of 29.10.2026. Details in the risk notice.